Biotechnology Companies in Belgium

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.

Our mission is to help life sciences companies accelerate drug development for improved patient outcomes, and we do this by championing the power of data. Our main product DISQOVER is an optimized search or knowledge platform which draws on semantic technology and an ontology-based knowledge graph to find links between data across databases (internal data, public data and third party data) faster and more efficiently. The platform has been developed for the pharmaceutical and biotech industries. There are thousands of health research databases, clinical trials, literature reviews, patient studies, etc. available. Before setting up a new study, scientists first need to check what kind of research has already been done – both internally and externally – on, for instance, growth hormone applications for a particular disease. In many companies, even internal information resides in hundreds of different databases, each with their own interface and search logic. As a consequence, just finding this kind of background information is a very time-consuming process. This is where DISQOVER comes in. One of the assets is that we use semantic technology to find logical but often hidden connections between internal and external data, allowing you to easily combine information from a multitude of different sources. As such, pharma and biotech companies can save valuable time and money that they can now invest in developing new medicines or treatments. Customers include: AstraZeneca, AmGen, Medidata, Prinses Máxima Institute, Aelin Therapeutics and more. DISQOVER is used amongst others by scientific researchers, bioinformaticians, and data scientists. Try DISQOVER: our community edition is always up-to-date and accessible via www.ontoforce.com (choose “try now” top right corner)

We bring automated cell-monitoring solutions for cell & gene therapy, vaccine industry and life sciences applications. Our microscopes are easy-to-use, label-free and non-invasive tools for the three-dimensional, real-time imaging of living cells. Based on patented differential digital holography technology, our advanced systems generate reliable, high-quality holographic images providing highly-reproducible tracking of: - cell density - morphology - cell viability - viral infection kinetics - cell activation status Direct Benefits Our technology can benefit a range of applications, from R&D to manufacturing processes, and enable significant cost reduction and quality improvement. Our microscopes are particularly convenient and robust for automated cell culture monitoring, analysis and quality control.

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a French-Belgian biotech company that develops an innovative class of active immunotherapies to treat cancers. This cancer vaccine contains proprietary, potent, and scalable plasmacytoid dendritic cell line (PDC*line), whose remarkable characteristics make them excellently suited for immunotherapy. PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors. PDC*line offers unique advantages: - PDC*line is a professional and universal antigen-presenting cell much more potent than conventional (myeloid) Dendritic cells; - unlike conventional autologous Dendritic Cells, PDC*line is very easy to expand in large quantities in bioreactors (no need of maturation factors) and having been exposed in vitro to targeted tumor antigens and irradiated, it can be stored for years. - The off-the-shelf product is thawed and injected to treat any patients with a cancer type expressing the selected antigens and expressing HLA-A2. Of note, different HLA may be used or added to extend the target population. - The approach is very versatile and applicable to any cancer type. Based on a first-in-human phase Ib study in melanoma, PDC*line Pharma focuses on the development of a clinical candidate for lung cancer (PDC*lung) and neoantigens (PDC*Neo). The company regroups a team of 42 persons led by Eric Halioua (CEO) and raised close to 61M€ in equity and loans since its foundation. March 2019, PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer. The total deal value is 108M€ (123M$) plus significant tiered royalties on net sales in Asia.

AXELEROS Preclinical Development is a Brussels-based preclinical development consultancy specializing in regulatory affairs and preclinical study management for the biopharmaceutical industry.

We support clients – including biotech companies, SMEs, and research institutions – throughout the entire preclinical process, from initial strategic planning to regulatory submission. Our team provides expert guidance on navigating the complex landscape of global regulations, ensuring your innovations meet the highest standards and accelerate their journey to market.

Our core services encompass a comprehensive suite of offerings, including strategic regulatory planning, global regulatory submissions, sourcing and management of toxicology and pharmacology studies, and toxicological risk assessments. We are dedicated to helping you bring your groundbreaking therapies to patients worldwide. We also offer European Public Affairs support to unlock valuable funding opportunities for your healthcare projects.

Affordable and clean technology for extending the shelf life of fruits and vegetables in developing counties. Smallholder farmers are the backbone of the economy in developing countries, of which woman carry more than their share. Their success or failure means the difference between eating and NOT eating for over 870 million people who are food insecure around the world. Smallholder farmers face an unsustainably high percentage of losses each and every year. According to the FAO, 45% of fruits and vegetables in developing countries never reach the consumer. That’s 45% less food in markets, on tables and in mouths. This postharvest loss is a result of smallholder farmers lacking adequate protection for their produce from the climate, pests and diseases. Nearly half of their investment of time and resources is needlessly wasted, resulting in higher prices for the entire population. “Improving the productivity, profitability, and sustainability of smallholder farming is the main pathway out of poverty in using agriculture for development.” Kofi Annan Reducing post-harvest losses is the most effective and sustainable solution to hunger and food insecurity. Wakati is a simple and innovative solution that alters the climate of fruit and vegetable storage spaces to increase shelf life and reduce post-harvest losses by over 20 percent. The climate control approach used by Wakati is a affordable and clean-technology. This life changing alternative increase the income by providing better quality and more crops by lowering the losses while the extended shelf live provides more time for growing crops, getting them on the marketplace and a better bargaining position to the local wholesalers.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

Univercells is a global life sciences company making biologics available to everyone. We operate as a campus of start-ups: six businesses solving different parts of the same puzzle - meeting global demand for bioproduction. Because it is not enough for a drug to exist. To change the world it must be accessible to everyone. Each division of affiliates operates a different part of the healthcare value chain, through a distinct business model: Univercells Technologies designs and produces cutting-edge manufacturing technologies for cell-based manufacturing, with an installed base in 70 countries. www.univercellstech.com. Exothera is a Contract Manufacturing and Development Organization (CDMO) for biologicals, mainly vaccines and viral vectors, with GMP production facilities in Belgium and offering process development and optimization services. https://exothera.world/. Unizima delivers international project management of technology transfer, alongside operational support services (quality, supply chain, digital) and bioproduction training programs, as well as care centers and diagnostics surveillance centers. https://unizima.com/. At Quantoom Biosciences, scientists, engineers and clinicians are committed to solve some of the biggest challenges facing mRNA-based vaccines and therapeutics by developing an end-to-end RNA Platform. This includes DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large-scale production. https://www.quantoom.com/. Thanks to a substantial knowledge of the pharmaceutical industry and a strong scientific background, RLM Consulting provides international regulatory affairs support at all stages of product development, from discovery research through preclinical and clinical testing, up to and beyond submission of the dossier for marketing authorization. http://www.rlmconsulting.be/.